Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Serina Therapeutics ( (SER) ) is now available.
On January 9, 2026, Serina Therapeutics received a deficiency notification from NYSE American stating the company is not in compliance with the exchange’s minimum stockholders’ equity requirements, after reporting equity of $1.6 million as of September 30, 2025 and losses in three of its four most recent fiscal years ended December 31, 2024. Serina has until February 8, 2026 to submit a remediation plan outlining actions to regain compliance by July 9, 2027, during which its shares will continue trading on NYSE American with enhanced oversight; acceptance of the plan would allow the company to remain listed through the cure period, while rejection would trigger delisting proceedings, creating added uncertainty for shareholders even as the company’s day-to-day operations and SEC reporting obligations remain unaffected in the near term.
The most recent analyst rating on (SER) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
The score is driven primarily by weak financial performance (large losses and significant cash burn with funding/dilution risk), reinforced by a bearish technical trend (price below major moving averages and negative MACD). Valuation provides limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, developing a pipeline of wholly owned drug candidates for neurological diseases and other indications using its proprietary POZ Platform drug-optimization technology. The POZ technology, based on a synthetic poly(2-oxazoline) polymer, is designed to enhance efficacy and safety of small molecules, RNA-based therapeutics and antibody-drug conjugates by improving drug loading and controlling release, and underpins Serina’s lead investigational Parkinson’s disease therapy, SER-252, as well as partnered applications such as a non-exclusive license with Pfizer for use in lipid nanoparticle delivery formulations.
Average Trading Volume: 46,216
Technical Sentiment Signal: Sell
Current Market Cap: $28.47M
For a thorough assessment of SER stock, go to TipRanks’ Stock Analysis page.